Arbutus Biopharma Corp Other Comprehensive Income (Loss), Net of Tax
Arbutus Biopharma Corp (ABUS) reported Other Comprehensive Income (Loss), Net of Tax of -$2.15 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-03-02
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for the quarter ending 2022-12-31 was $516.00K.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$907.00K, a 7658.33% decline year-over-year.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$691.00K.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for the quarter ending 2022-03-31 was -$1.07M, a 35800.00% decline year-over-year.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for fiscal 2022 was -$2.15M.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for fiscal 2021 was -$164.00K, a 1271.43% decline from fiscal 2020.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for fiscal 2020 was $14.00K.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax for fiscal 2019 was -$59.00K, a 493.33% decline from fiscal 2018.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $516.00K derived: 10-K 12 month − 3 quarters · filed 2023-03-02 | -$391.00K derived: sum of 2 quarters · filed 2023-03-02 | -$1.08M derived: sum of 3 quarters · filed 2023-03-02 | -$2.15M 10-K · filed 2023-03-02 |
| 2022-09-30 | -$907.00K 10-Q · filed 2022-11-09 | -$1.60M derived: sum of 2 quarters · filed 2022-11-09 | -$2.67M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2022-06-30 | -$691.00K 10-Q · filed 2022-11-09 | -$1.76M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2022-03-31 | -$1.07M 10-Q · filed 2022-11-09 | |||
| 2021-12-31 | -$164.00K 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $12.00K 10-Q · filed 2022-11-09 | -$19.00K derived: sum of 2 quarters · filed 2022-11-09 | -$16.00K derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$31.00K 10-Q · filed 2022-11-09 | -$28.00K derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $3.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $14.00K 10-K · filed 2022-03-03 | |||
| 2020-09-30 | -$72.00K 10-Q · filed 2021-11-04 | -$194.00K derived: sum of 2 quarters · filed 2021-11-04 | $58.00K derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$122.00K 10-Q · filed 2021-11-04 | $130.00K derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $252.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | -$59.00K 10-K · filed 2020-03-05 | |||
| 2019-09-30 | $27.00K 10-Q · filed 2019-11-06 | -$25.00K derived: sum of 2 quarters · filed 2020-08-07 | -$47.00K derived: sum of 3 quarters · filed 2020-08-07 | |
| 2019-06-30 | -$52.00K 10-Q · filed 2020-08-07 | -$74.00K derived: sum of 2 quarters · filed 2020-08-07 | ||
| 2019-03-31 | -$22.00K 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $15.00K 10-K · filed 2019-03-07 | |||
| 2018-09-30 | -$12.00K 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |